Interspecies Variation of In Vitro Stability and Metabolic Diversity of YZG-331, a Promising Sedative-Hypnotic Compound

Zhihao Liu1,2†, Yakun Yang1†, Li Sheng1* and Yan Li1

1 Department of Drug Metabolism, Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2 Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China

YZG-331, a synthetic adenosine derivative, express the sedative and hypnotic effects via binding to the adenosine receptor. The current study was taken to investigate the metabolic pathway of YZG-331 as well as species-specific differences in vitro. YZG-331 was reduced by 14, 11, 6, 46, and 11% within 120 min incubation in human, monkey, dog, rat, and mouse liver microsomes (LMs), respectively. However, YZG-331 was stable in human, monkey, dog, rat, and mouse liver cytoplasm. In addition, YZG-331 was unstable in rat or mouse gut microbiota with more than 50% of prototype drug degraded within 120 min incubation. Interestingly, the systemic exposure of M2 and M3 in rats and mice treated with antibiotics were significantly decreased in the pseudo germ-free group. YZG-331 could be metabolized in rat and human liver under the catalysis of CYP enzymes, and the metabolism showed species variation. In addition, 3 phase I metabolites were identified via hydroxyl (M1), hydrolysis (M2), or hydrolysis/hydroxyl (M3) pathway. Flavin-containing monoxygenase 1 (FMO1) and FMO3 participated in the conversion of YZG-331 in rat LMs. Nevertheless, YZG-331 expressed stability with recombinant human FMOs, which further confirmed the species variation in the metabolism. Overall, these studies suggested that YZG-331 is not stable in LMs and gut microbiota. CYP450 enzymes and FMOs mediated the metabolism of YZG-331, and the metabolic pathway showed species difference. Special attention must be paid when extrapolating data from other species to humans.

Keywords: YZG-331, metabolism, CYP450, FMOs, species variation

INTRODUCTION

Insomnia is a common problem which has a direct impact on the physical and mental health (Ohayon, 2002). Sedative-hypnotic medication is considered as an important strategy to relieve insomnia (Bertisch et al., 2014). Insomnia medications that are commonly used in clinical treatment mainly focus on the γ-aminobutyric acid receptor, melatonin receptor, orexin, and serotonin site (Zisapel, 2012, 2015). Although effective, they also have some adverse effects including somnolence, dizziness, nausea, headache and hallucinations (Griffiths et al., 1986;
Bocca et al., 1999). Based on the complex mechanisms of sleep, several new mechanisms and novel targets have been proposed for treating sleep-wake disorders. To meet divergent medical needs, it is essential to develop novel sedative-hypnotic drugs aiming at new therapeutic targets.

Adenosine is an important endogenous sleep-promoting factor. It not only induces sleep during waking periods, but also exhibits a major role in the modulation of sleep duration or factor. It not only induces sleep during waking periods, but also aiming at new therapeutic targets.

Based on the comprehensive evaluation of pharmacodynamic derivatives for sedative and hypnotic activity was conducted. Detailed structure-effects relationship research of more than 150 adenosine analogs. As far, the research of adenosine analogs for atrial fibrillation, autoimmune diseases and chronic hepatitis C are in clinical trials (Samsel and Dzierzbicka, 2016). In particular, clarification the metabolic pathway and comparison the species differences are vital for prediction of clinical efficacy and species selection for safety studies and solvents were commercially available.

**Materials and Methods**

**Chemicals and Reagents**

YZG-331, M2, and YZG-441 (purity ≥ 99%) were obtained from the Department of Natural Products Chemistry (Institute of Materia Medica, Chinese Academy of Medical Sciences). NADPH, NADH, β-NADP, glucose-6-phosphate (6-G-P), glucose-6-phosphate dehydrogenase (6-G-P-DH), midazolam, vanillin, 4-methylumbelliferol-β-d-glucuronide (4MUG), benzydynamine and aminobenzotriazole (ABT) were the products of Sigma Aldrich (St. Louis, MO, United States).

**Animals**

Male ICR mice (20–22 g) and Sprague–Dawley rats (220–250 g) were purchased from Vital River Experimental Animal Co., Ltd (Beijing, China). Standard pelleted laboratory chow and water were allowed ad libitum. All experiments were approved by the Animal Care and Use Committee of Peking Union Medical College, and were strictly taken in accordance with Legislation Regarding the Use and Care of Laboratory Animals of China.

**In Vitro Metabolism Studies**

For the LMs stability study, YZG-331 (0.5 μM) was incubated with human, monkey, dog, rat, and mouse LMs (1 mg/mL) in Tris-HCl buffer (50 mM, pH 7.4, 200 μL) containing MgCl₂ (5 mM). The medium containing YZG-331 was incubated at 37°C for 5 min, and then NADPH-regenerating system (10 mM β-NADP, 100 mM 6-G-P and 10 U/mL 6-G-P-DH) was added to initial the reaction. The samples were obtained at 15, 30, 45, 60, 90, and 120 min after incubation. All reactions were conducted in triplicate and terminated by adding 400 μL ice-cold acetonitrile. The remaining fraction of YZG-331 was quantified by LC-MS/MS assay. Midazolam (5 μM) was set as the positive control.

For the liver cytosols stability study, human, monkey, dog, rat, and mouse liver cytosols stability study was taken to investigate the metabolic stability of YZG-331. The reaction system contained phosphate buffer (50 mM, pH 7.4, 200 μL) with MgCl₂ (5 mM), liver cytosols protein (0.5 mg/mL) and YZG-331 (0.5 μM). The samples were collected at 30 min after incubation. All reactions were conducted in triplicate, and then ice-cold acetonitrile (400 μL) was added to terminate the reaction. The remaining fraction of YZG-331 was quantified by LC-MS/MS assay. Vanillin (1 μM), the typical substrate of aldehyde oxidase (AOX), was set as the positive control in the reaction.
For the gut microbiota stability study, the method was taken as described previously (Feng et al., 2015). In short, fresh feces (obtained from six rats/mice) were added into 100 mL anaerobic medium. After mixed thoroughly, the medium was firstly incubated under an anaerobic environment containing N2 atmosphere. Ten microliters of YZG-331 was added into the medium (500 µL) to obtain the final concentration of 5 µg/mL. The cultures were incubated at 37°C. All reactions were conducted in triplicate and terminated by acetonitrile at designated time points (0, 15, 30, 60, 120 min). The remaining fraction of YZG-331 was quantified by LC-MS/MS assay.

Intestinal bacteria from pseudo germ-free (PGF) rats and mice were used to further investigate the role of intestinal bacteria in the metabolism of YZG-331. Briefly, male rats or mice were orally given cefadroxil (100 mg/kg) twice a day for 3 days to reduce gastrointestinal bacteria levels, and the colon contents of the animals were harvested after the last treatment of antibiotics. Furthermore, 4MUG (5 µg/mL), a substrate of intestinal bacterial β-glucuronidase, were used as the positive control for the fecal incubation system.

**Identifications of YZG-331 Metabolites**

To identify metabolites, YZG-331 (10 µM) was incubated with LMs (human, monkey, dog, rat, mouse) or gut microbiota as described above. In addition, the incubation of YZG-331 with gut microbiota was terminated by high temperature inactivation (90°C, 5 min). Then, the supernatant samples were continued to incubate with LMs. Briefly, the mixed medium contained phosphate buffer (50 mM, pH 7.4) with MgCl2 (5 mM), LMs protein (0.5 mg/mL), NADPH-regenerating system and supernatant of gut microbiota incubation (10 µL) in a total volume of 200 µL. The incubation was terminated by acetonitrile after 30 min and centrifuged at 14,000 rpm for 5 min. Then the samples were analyzed by LC-MS/MS.

**Identification of Enzymes Responsible for the Hydroxylation of YZG-331 in LMs**

The contributions of CYP450s and FMOs to the metabolism of YZG-331 and M2 in rat LMs were investigated by using a nonspecific CYPs inhibitor ABT and thermal inactivation of FMOs. YZG-331/M2 (0.5 µM) was incubated with rat LMs (1 mg protein/mL) with or without ABT (1 mM) for 30 min and the reaction was stopped with 2 volumes of acetonitrile. Thermal inactivation of FMOs was carried out by preheating rat LMs (1 mg protein/mL) at 50°C for 5 min. Then rat LMs was immersed in ice-cold bath followed by addition of YZG-331/M2 (0.5 µM). After a 3 min equilibration, the reaction was started by NADPH. The incubation was stopped after 30 min by adding 2 volumes of acetonitrile. The mixtures were centrifuged at 14,000 rpm at 4°C for 5 min, and supernatant samples were determined using LC-MS/MS. In this study, benzydamine (20 µM), a known substrate of FMO, was used as the positive control for FMO activity. The retained activity of CYPs was confirmed by using midazolam (a CYP3A substrate). The remaining fraction of YZG-331 and metabolites of control drugs were analyzed using LC-MS/MS.

Human cDNA-expressed CYPs were used to investigate the enzymes mediated the metabolism of YZG-331. YZG-331 (0.5, 2, and 5 µM) and 20 pmol of thirteen individual human cDNA expressed CYPs (CYP1A1, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4, 4A11, 4F2, and 4F3) and three cDNA expressed FMO enzymes (50 pmol/mL FM01, FM03, and FM05) under the conditions similar to those of rat LMs (described above), except incubating time (120 min). Probe substrates of CYPs were used as the positive controls, and the incubation without NADPH served as the negative controls.

**In Vivo Studies in PGF Rats and Mice**

Male rats or mice were orally treated with cefadroxil (100 mg/kg) for 3 days as described above, then in vivo study was taken 2 days after the antibiotic treatment. The rats were oral received a single dose of YZG-331 (50 mg/kg for rats, 20 mg/kg for mice). Then blood was harvested immediately through posterior orbital venous plexus at 0, 0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 h post-YZG-331 treatment. Plasma (100 µL for rats, 10 µL for mice) was immediately centrifuged at 5000 rpm for 10 min. The samples of plasma from rats or mice were prepared as describe before (Liu et al., 2014, 2016).

**LC-MS/MS Determination**

The samples were quantified by HPLC-MS/MS consisted of mass spectrometer (API4000; Applied Biosystems, USA), HPLC system (1260; Agilent, United States) and Zorbax SB-C18 column (3.5 mm, 2.1 mm × 100 mm, Agilent, Santa Clara, CA, United States). An electrospray ionization (ESI) source was used in positive mode. The mobile phase for YZG-331, Midazolam, 4-MUG and benzydamine consisted of acetonitrile/water (0.1% formic acid). The mobile phase for vanillin consisted of solvent A (1 mM ammonium acetate in methanol) and solvent B (0.05% ammonia in water). The ionization was conducted using a positive ion mode for YZG-331, Midazolam, benzylamine, and 4MUG and in negative ion mode for vanillin. The selected transitions of m/z were m/z 386.2 → 254.2 for YZG-331, 338.7 → 291.3 for midazolam, 310.0 → 264.9 for benzydamine, m/z 166.2 → 151.8 for vanillin and 338.7 → 177.4 for 4MUG. The flow rate was 0.2 mL/min and the operating temperature was 25°C for all determinations.

For the metabolites detection, full-scan MS spectra was used to measure the masses of YZG-331 and its metabolites. The mass spectrometer was selected in the positive ion mode in the mass range of m/z 100-800. The MS/MS spectra were produced by collision-induce dissociation of the selected precursor ions. The mobile phase consisted of water (A)/acetonitrile (B) (0.1% formic acid) with a flow rate of 0.2 mL/min. The following condition was used: 90% A at 0-6 min, 90-10% A at 6–15 min, 10–90% A at 15–25 min. Then, the starting conditions were reestablished and balanced for 2 min. The sample injection volume was 10 µL. The parameters were selected to get maximum sensitivity at the unit resolution.

**Data Analysis**

The pharmacokinetic parameters for YZG-331/M2 in plasma were determined by noncompartmental analysis using Phoenix
FIGURE 1 | Stability of YZG-331 in liver microsomes (LMs) of human, dog, monkey, mouse, and rat in vitro. Positive control midazolam (0.5 µM, A) and YZG-331 (0.5 µM, B) was incubated at 37°C for 120 min in for all species. The control groups for (A) represent the content of midazolam or YZG-331 in the inactivate microsomes. The reaction groups for (A) represent the remain content of midazolam after incubating with NADPH at 37°C for 30 min. (B) Represents the remain content of YZG-331 after incubating with NADPH at 37°C for 120 min. Each column is the mean ± SD of triplicate determinations. Statistical differences of each point were compared with those for the control groups by a two-tailed unpaired t-test, with *p < 0.05 as the limit of significance (**p < 0.01 vs control; *p < 0.05 vs. control).

FIGURE 2 | Stability of YZG-331 in liver cytosol of human, dog, monkey, mouse, and rat in vitro. (A) The positive control vanillin (1 µM) incubated at 37°C for 30 min in liver cytosol for all species; (B) YZG-331 (0.5 µM) was incubated at 37°C for 30 min in liver cytosol for all species. The control groups represent the content of vanillin or YZG-331 in the inactivate liver cytosol. Each column is the mean ± SD of triplicate determinations. Statistical differences of each point were compared with those for the control groups by a two-tailed unpaired t-test, with *p < 0.05 as the limit of significance (**p < 0.01 vs control; *p < 0.05 vs. control).

WinNonlin 6.3 (Pharsight Corporation, Mountain View, CA, United States). Statistical analyses between the two groups were performed with a two-tailed Student's t-test, while multi-comparisons were performed using one-way ANOVA. Values of p < 0.05 were considered to statistically significant. The contents of metabolites from LMs incubation were evaluated by principal component analysis (PCA) using SPSS software (Li et al., 2016; Ma et al., 2016).

RESULTS

Metabolism of YZG-331 in Liver Microsomal/Cytosolic Fractions and Gut Microbiota

As preliminary identification of the possible metabolites and metabolic pathway, incubations were taken in human, monkey, dog, rat, and mouse LMs and cytosolic fractions with YZG-331 as the substrate. The results were shown in Figure 1. The positive control midazolam, a substrate of CYPs, was decreased by more than 90% in the presence of NADPH in all species of LMs, indicating the LM systems was reliable. Approximately 46% of YZG-331 was metabolized in rat LMs in the presence of NADPH. Less than 20% of YZG-331 was diminished in human, monkey, dog, and mouse LM systems. In addition, the positive control vanillin, a substrate of AOX, was reduced in human liver cytosol (Figure 2). However, YZG-331 was stable in all species of cytosol, which suggested that cytosolic enzymes are not involved in the metabolism of YZG-331.

Furthermore, we investigated whether gut microbiota is responsible for the biotransformation of YZG-331. Our data showed that YZG-331 was unstable in rat or mouse gut microbiota with more than 50% of prototype drug degraded in 120 min (Figure 3A). On the other hand, gut microbiota obtained from PGF rats or mice was taken to confirm that gut microbiota was responsible for the conversion of YZG-331. As shown in Figure 3B, antibiotics treatment inhibited the bacterial mediated metabolism of 4MUG, suggesting an intestinal bacteria scarcity environment in the animals. As expected, the lack of intestinal bacteria resulted in a low level of metabolism of YZG-331 (Figure 3C), implying that gut microbiota can act as an "organ" that involved in the conversion of YZG-331. Subsequently, metabolite identification following incubation was conducted.
Identification of Metabolites of YZG-331

In Vitro

In total, three metabolites were identified from the incubated YZG-331 in the LMs of five different species using LC-MS/MS (Figures 4, 5). Among these, the molecular of M1 (m/z 402) was showed 16 Da higher than that of YZG-331, indicating that it would be the hydroxylation of parent drug. M2 (m/z 254) was the hydrolysis product of parent drug at the site of N9 terminal of N6-(4-hydroxybenzyl) adenine through the C–N bond. The molecular of M3 (m/z 270) was 16 Da higher than that of M2, indicating that it would be hydroxylation metabolite of M2 or hydrolysis product of M1. M2 was identified as the major metabolite via gut microbiota conversion (Figure 6), suggesting hydrolyization was the critical pathway of the parent compound in gut microbiota. Interestingly, M3 was detected when the supernatant of gut microbiota was incubated in the LMs system, confirming that M3 was the hydroxyl style of M2. The detailed information, structures, contents of metabolites and total ion chromatograms of YZG-331 metabolites are shown in Table 1.

Compared with other species, metabolite content in rat LMs is relatively high (Figure 4).

In Vivo Pharmacokinetics of YZG-331 in PGF Rats and Mice

As shown in Figures 7A,D, absorption of YZG-331 was rapid after oral administration. The plasma concentrations of YZG-331 were maximal at 0.25 h in mice and within 2 h in rats. The mean peak concentration (C_{max}) of YZG-331 in mice after a single oral administration at 20 mg/kg was 4.07 µg/mL, whereas C_{max} was 4.4 µg/mL in rats at a dose of 50 mg/kg. The mean residence times (MRT) were 2.63 ± 0.84 h and 3.45 ± 0.29 h in rats and mice, respectively. To investigate the role of gut microbiota in the pharmacokinetics of YZG-331, we used PGF rats and mice in the study. As shown in Figure 7 and Table 2, the systemic exposure of YZG-331 was not changed obviously in rats and mice with antibiotics compared with non-antibiotic group. However, the C_{max} and AUC values of M2 and M3 in rats and mice treated with antibiotics were significantly
FIGURE 5 | The extracted ion chromatograms of YZG-331 metabolites in rat LMs. YZG-331 (10 μM) was incubated at 37°C for 120 min for all species. The MS/MS spectra was acquired for the accurate measurement of the masses of YZG-331 and its metabolites. The figure only expressed the chromatograms from rat liver microsomes (LMs) were selected as the representative.
The gut microbiota cultures of YZG-331 (10 µM) were incubated at 37°C for 120 min. (C,D) The supernatant obtained from the gut microbiota incubation was continued to incubate with rat LMs at 37°C for 120 min. The MS/MS spectra was acquired for the accurate measurement of the masses of YZG-331 and its metabolites.

Figure 6: The extracted ion chromatograms of M2 and M3 in gut microbiota or LMs system from supernatant of gut microbiota. (A,B) The gut microbiota cultures of YZG-331 (10 µM) were incubated at 37°C for 120 min. (C,D) The supernatant obtained from the gut microbiota incubation was continued to incubate with rat LMs at 37°C for 120 min. The MS/MS spectra was acquired for the accurate measurement of the masses of YZG-331 and its metabolites.

decreased in PGF group (p < 0.05, Figure 7 and Table 3). The results suggested that the antibiotic-induced decrease in intestinal bacteria resulted in a low level of conversion of YZG-331 into M2 in the intestine and thus a low level of M2 as well as M3 in the blood.

Identification of Enzymes Responsible for the Metabolism of YZG-331 in LMs

Rat LMs was used to further determine whether the CYPs were responsible for the metabolism of M1, M2 and M3. As shown in Figure 8A, the CYPs inhibitor ABT could strongly reduce the metabolism of CYP3A4 substrate midazolam but not the negative control benzydamine, which suggested the system was reliable. The metabolism of YZG-331 and M2 was also blocked in the incubation mixtures in the presence of ABT (Figure 8A). When YZG-331 was incubated with rat LMs, M1, M2, and M3, were decreased in the presence of ABT (Figure 8B). The results clearly showed that CYPs were responsible for the formation of M1, M2, and M3.
TABLE 1 | Metabolic reaction, nominal mass shift, and MS/MS fragments of YZG-331 and its metabolites.

| Metabolites | Metabolic reaction | [M+H]+ Nominal mass shift | MS/MS fragments |
|-------------|--------------------|---------------------------|-----------------|
| YZG-331     |                    | 386                       | 254, 136, 119   |
| M1          | Hydroxylation      | 402 +16                   | 270, 136        |
| M2          | Hydrolyzation      | 254 −132                  | 136, 119        |
| M3          | Hydrolyzation +    | 270 −132+16               | 136, 152        |

Toward a more detailed understanding of the roles of CYP enzymes in the biotransformation of YZG-331, the contribution of 13 recombinant human CYP enzymes in the metabolism of YZG-331 was investigated. As shown in Figure 9, the recombinant CYP2J2 showed the highest metabolic activity for the formation of M1 and M3, while the recombinant CYP2C9 and CYP2C19 was involved in the formation of M1 and M3. Moreover, recombinant CYP1A2 and CYP3A4 may also participate in the formation of M1 and M3 to a certain extent.

To distinguish between the contributions of FMOs and CYPs to the metabolism, incubations can be carried out on microsomes that have been preheated at 50°C in the absence of NADPH, which knocks out FMOs activity. As expect, we found that the metabolism of benzydamine (known substrate of FMOs) other than midazolam (known substrate of CYP3A4) was strongly decreased at the condition 50°C (Figure 10A), which suggested that the activity of FMOs was successfully knocked out. In our study, the metabolism of YZG-331 was effectively inhibited by the thermal inactivation of FMOs, resulting in a 30% reduction in M2 formation and 50–60% decrease in the formation of M1 and M3 (Figure 10B). Thus, FMOs may also play a role in YZG-331 metabolism.

To further confirm the role of human FMOs in the metabolism of YZG-331, we examined the metabolism of YZG-331/M2 with recombinant human FMOs. As shown in Figure 11A, benzydamine was not stable in hFMO1 and hFMO3 but not hFMO5 in the presence of NADPH. Probably because that FMO5 displays no or poor reactivity toward classical FMO substrates.

TABLE 2 | Pharmacokinetic parameters of YZG-331 in rats and mice after a single oral administration of YZG-331.

| Parameter | Unit | Rat<sup>a</sup> | Mouse<sup>b</sup> |
|-----------|------|----------------|-----------------|
|           |      | Control        | PGF             | Control | PGF |
| T<sub>1/2β</sub> | h    | 4.14 ± 1.38    | 5.85 ± 1.56     | 6.28 ± 3.02 | 5.26 ± 2.62 |
| T<sub>max</sub>  | h    | 1.10 ± 0.55    | 0.55 ± 0.27     | 0.25 ± 0.23 | 0.2 ± 0.18  |
| C<sub>max</sub>  | ng/mL| 4441 ± 1718    | 3936 ± 1814     | 4072 ± 663 | 3620 ± 1185 |
| AUC<sub>(0-t)</sub>| h·ng/mL| 11009 ± 4572 | 11186 ± 6615 | 10717 ± 1318 | 10417 ± 2546 |
| AUC<sub>(0-∞)</sub>| h·ng/mL| 11155 ± 4482 | 12048 ± 6426 | 11338 ± 1206 | 10936 ± 2450 |
| MRT<sub>(0-t)</sub> | h    | 2.63 ± 0.84    | 4.49 ± 1.20     | 3.45 ± 0.29 | 3.77 ± 0.92  |
| MRT<sub>(0-∞)</sub> | h    | 3.24 ± 1.76    | 6.98 ± 3.31     | 5.20 ± 1.49 | 5.19 ± 1.86  |

Data shown are the means ± SD, n = 5 for each group.
<sup>a</sup>50 mg/kg, p.o.; <sup>b</sup>20 mg/kg, p.o.
and, consequently, was believed not to play a significant role in drug conversion (Phillips and Shephard, 2017). However, no metabolites of YZG-331 were observed in the incubations with recombinant FMO1, FMO3, and FMO5 (Figures 11B,C).

**Comparison of YZG-331 Metabolism among Different Species**

In view of the metabolism data, PCA was conducted during different species. The PCA score scatter plots of rat LMs expressed distinctive and discrete clusters for other species (Figure 12), implying an interspecies difference for YZG-331 metabolism. According to the PCA results, the human groups were clustered with dog groups. Furthermore, the monkey groups and dog groups cluster together.

**DISCUSSION**

Drug metabolism research is an indispensable part at various stages of drug discovery and development (Yan and Caldwell, 2001). YZG-331 is an attractive sedative hypnotic candidate. A comprehensive investigation into the metabolic pathways involved in the clearance of YZG-331 can reveal the pharmacological activities and toxicological implications to ensure safe and effective use of the drug (Xiao et al., 2012).

It is well accepted that intestinal bacteria has an irreplaceable role in the conversion of orally administrated drugs (Yao et al., 2016). Before being absorbed through the intestinal barrier, drugs may be transformed by intestinal bacteria leading to the occurrence of more active, toxic or ineffective compounds. This course is vital for whether drug candidates will become therapeutics. As a promising sedative-hypnotic drug, YZG-331 would be administered orally and inevitably lead to contact with intestinal microflora in the gastro-intestinal tract and subsequently be transformed by intestinal bacteria before being absorbed into the blood. YZG-331 could be firstly converted to its hydrolysis form (M2) by the majority of the isolated intestinal bacteria (Figures 3, 6). This study presents an interesting case to show the importance of the gut microbiota in modifying M2 systemic exposure. Oral administration of antibiotics decreased the amount of intestinal bacteria and, consequently, was believed not to play a significant role in the conversion of orally administrated drugs (Yao et al., 2016).
FIGURE 9 | Effects of CYP450 on the metabolism of YZG-331 in human cDNA expressed CYPs system. (A) YZG-331 (0.5, 2, and 5 µM) and 20 pmol of thirteen individual human cDNA expressed CYPs (CYP1A1, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4, 4A11, 4F2, and 4F3) were incubated at 37°C for 30 min. (B,C) The production of M1 (B) and M3 (C) from YZG-331 mediated by recombinant human CYPs. Each column is the mean ± SD of triplicate determinations.

In the study, we found that, compared with M1 and M3, the generation of M2 was not significantly influenced by ABT in rat LMs. The results indicated that M2 was not mainly converted by microsome enzymes. Thereby, the hydrolysis product M2 could be mostly generated by gut microbiota. In contrast, the hydroxyl products M1 and M3 could be generated by the enzymes expressed in the liver. To sum up the evidence, we deduce that YZG-331 was firstly, at least in part, converted to M2 by the intestinal bacteria, and M3 was the hydroxyl style of M2.

Previous studies have shown that there were some differences in the efficacy of YZG-331 between mice and rats. Generally, rats require a higher dose to achieve similar efficacy to mice. Correspondingly, the $C_{\text{max}}$ of YZG-331 in mice after oral
administration of 20 mg/kg was comparable to that of rat at a dose of 50 mg/kg. The metabolic stability study of drugs in LMs helps to assess the contribution of the first pass effect to bioavailability. In the present study, the metabolism of YZG-331 was thoroughly investigated using liver microsomes/cytosol from different species in vitro. Interestingly, significant variations have been observed between species in the current study. YZG-331 was found to be metabolized faster in rat LMs than in other four species (Figure 1). AOX and xanthine oxidase are two important cytosolic enzymes (Sperling, 2012). They participate in the metabolism of some important purine related drugs, such as azathioprine and vidarabine. However, YZG-331 was relatively stable in the liver cytoplasm of all the species (Figure 2), which suggested microsomes would be the target site for the metabolism and species difference. The large differences in the elimination of YZG-331 suggested that the interspecies extrapolation from animals to human should be aware.

CYPs, which constitute a heme-containing superfamily, are responsible for the bulk of the oxidative metabolism of known drugs in humans. In this study, we identified the enzymes responsible for the oxidative metabolism of YZG-331. As expected, multiple CYPs were found to be involved in the oxidative metabolism of YZG-331 by recombinant enzymes. In the study, YZG-331 is confirmed to be metabolized by rat CYPs to yield a hydroxyl product, M1, as the main circulating metabolite (Figures 4, 8). Several human CYPs consistently metabolized the YZG-331 screened in the present study, which revealed that YZG-331 would be widely metabolized in vivo and probably affected by many factors. Among them, CYP2C8, 2C9, 2C19, CYP2J2, and CYP3A4-mediated formation of M1 and M3, indicates that YZG-331 mainly undergoes hydroxylation reaction in liver (Figures 9B,C). Apart from CYP3A and 2C family, CYP2J2 belongs to a relatively newer CYP subfamily (Karkhanis et al., 2017). Intriguingly, CYP2J2 attained important role of M1 and M3 production in human LMs, even with low concentrations of YZG-331. We postulated there was relative high affinity between CYP2J2 and YZG-331, resulting in the considerable production of M1 and M3 in human LMs. This multiple metabolism pathway would decrease the potential of risk in the application of YZG-331 in the clinic.

According to the results, the stability of YZG-331 was remarkably varied in different species, and it could be partly related to CYP differences among species. Although CYPs are highly conserved among species, there are still some variation in the amino acid sequences (Martignoni et al., 2006). However, even small changes in the amino acid sequences could lead to large variation in substrate selectivity and catalytic activity. Thus, differences in CYPs could result profound variations in drug metabolism (Guengerich, 1997). In the study, it was suggested that YZG-331 was not stable in rat LMs which could be partly contributed by CYPs. The assessment of CYP isoforms would be helpful in identifying and understanding interspecies variation of YZG-331. In addition, the knowledge of species differences of YZG-331 mediated by CYPs will also help to extrapolate date obtained from animals to human reasonably well. However, till now, it was difficult to identify the isoforms mediated the
metabolism in rats. It is well known that all main human individual human cDNA expressed CYPs are now commercially available (Martignoni et al., 2006). Nevertheless, for other species, the recombinant expressed individual CYPs are scarcely available.

Principal component analysis was further introduced to compare the variation in different species in YZG-331 conversion. The PC score plots showed specificity and dispersed clusters for different species (Figure 12), suggesting a characteristic interspecies difference for YZG-331 conversion. It is indicated that the CYPs polymorphism and enzymatic activity differences could cause variation in the metabolism of YZG-331. Therefore, it could increase the complexity when extrapolating data from animals to humans.

Our further research suggested that YZG-331 was metabolized by both FMOs and CYPs. It was well accepted that FMOs and CYPs share some substrates in common but often produce different metabolites (Guengerich, 2001). For most cases, the contribution of FMOs to drug metabolism might be underestimated, therefore, the number of drugs identified as being metabolized by FMOs is relatively small (Taniguchi-Takizawa et al., 2015). In contrast to CYPs, FMOs are not readily induced or inhibited by foreign chemicals (Phillips and Shephard, 2017). These differences between FMOs and CYPs indicate that drugs that are metabolized predominantly by FMOs would be less likely to elicit drug-drug interactions and potentially harmful side effects, and therefore the design of YZG-331 would offer clinical advantages. However, our results indicated that the metabolism of YZG-331 mediated by FMOs showed species variation (Figures 10, 11). In fact, various studies suggested that FMOs showed regional-specific expression and the species difference. There are distinct differences between the species in the metabolism of drugs in vivo by FMOs. For instance, drug substrates of FMO1 will be metabolized in mouse, but not human, liver; substrates of FMO2 will be metabolized in mouse, but not in the majority of humans (Phillips and Shephard, 2017). What is more, the relative contribution to overall activity of rat FMO1 in rat LMs was different from that of monkey and human FMO3. Recombinant expressed rat FMO1 had high affinity for...
the substrates with the exception of tozasertib (Yamazaki et al., 2014).

CONCLUSION

Our results confirmed that YZG-331 could be metabolized by multiple pathways, including LMs and intestinal bacteria. CYP450 enzymes and FMOs mediated the metabolism of YZG-331, and the metabolic pathway showed species difference. Species variation in YZG-331 metabolism could affect the accuracy of the extrapolation from animals to humans.

ETHICS STATEMENT

This study was conducted in accordance with the recommendations of Legislation Regarding the Use and Care of Laboratory Animals of China, and the protocol was approved by Animal Care and Use Committee of Peking Union Medical University.

REFERENCES

Bertisch, S. M., Herzig, S. J., Winkelman, J. W., and Buettner, C. (2014). National use of prescription medications for insomnia: NHANES 1999-2010. Sleep 37, 343–349. doi: 10.5665/sleep.3410

Bocca, M. L., Le Doze, F., Etard, O., Pottier, M., L’hoste, J., and Denise, P. (1999). Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology 143, 373–379. doi: 10.1007/s002130050961

Chen, J. F., Eltzschig, H. K., and Fredholm, B. B. (2013). Adenosine receptors as drug targets—what are the challenges? Nat. Rev. Drug Discov. 12, 265–286. doi: 10.1038/nrd3955

Feng, R., Shou, J. W., Zhao, Z. X., He, C. Y., Ma, C., Huang, M., et al. (2016). Interspecies metabolites in rat urine and plasma of N-demethylation of a benzamide by cytochrome P450 and flavin-containing monooxygenase. Drug Test. Anal. 8, 754–768. doi: 10.1002/dta.2028

Liu, Z., Mi, J., Yang, S., Zhao, M., Li, Y., and Sheng, L. (2016). Effects of P-glycoprotein on the intestine and blood-brain barrier transport of YZG-331, a promising sedative-hypnotic compound. Eur. J. Pharmacol. 791, 339–347. doi: 10.1016/j.ejphar.2016.08.039

Liu, Z., Sheng, L., and Li, Y. (2014). Determination of YZG-331 in mouse plasma using liquid chromatography–tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 944, 6–10. doi: 10.1016/j.jchromb.2013.10.041

Ma, Y., Xie, W., Tian, T., Jin, Y., Xu, H., Zhang, K., et al. (2016). Identification and comparative oridonin metabolism in different species liver microsomes by using UPLC–Triple-TOF-MS/MS and PCA. Anal. Biochem. 511, 61–73. doi: 10.1016/j.ab.2016.08.004

Martignoni, M., Groothuis, G. M., and De Kanter, R. (2006). Species differences related to metabolism and chemical toxicity. Chem. Res. Toxicol. 19, 611–650. doi: 10.1021/tx0602583

Phillips, I. R., and Shephard, E. A. (2017). Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin. Drug Metab. Toxicol. 13, 167–181. doi: 10.1080/17425255.2017.1239718

Samsel, M., and Dzierzbicka, K. (2011). Therapeutic potential of adenosine analogues and conjugates. Pharmacol. Rep. 63, 601–617. doi: 10.1016/j.pharmrep.2011.11.007

Shenoy, A. K., Miyahara, J. T., Swinyard, E. A., and Kupferberg, H. J. (1982). Comparative anticonvulsant activity and neurotoxicity of clobazam, diazepam, phenobarbital, and valproate in mice and rats. Epilepsia 23, 399–408. doi: 10.1111/j.1345-5188.1982.tb05426.x

Sperling, O. (2012). Purine Metabolism in Man: Enzymes and Metabolic Pathways. Berlin: Springer.

Taniguchi-Takizawa, T., Shimizu, M., Kume, T., and Yamazaki, H. (2015). Benzoylamine N-demethylation by cytochrome P450 enzymes in human microsomes from rats, dogs, monkeys, and humans. Drug Metab. Pharmacokinet. 30, 64–69. doi: 10.1016/j.dmpk.2014.09.006

Xiao, J. F., Zhou, B., and Ressom, H. W. (2012). Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends Anal. Chem. 32, 1–14. doi: 10.1016/j.trac.2011.08.009

Yamazaki, M., Shimizu, M., Uno, Y., and Yamazaki, H. (2014). Drug oxidation activities mediated by liver microsomal flavin-containing monooxygenases

AUTHOR CONTRIBUTIONS

LS and YL participated in research design; ZL, YY, and LS conducted the experiments and data analysis; ZL and LS wrote or contributed to the writing and revision of the manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (Nos. 81603190), National Science and Technology Major Project for “Major New Drugs Innovation and Development” (2017ZX09101003-002-001), Public Science and Technology Research Funds Projects (201402001), and CAMS Innovation Fund for Medical Sciences (2016-I2M-3-011).

ACKNOWLEDGMENTS

The authors thank Professor Shi Jiangong and Zhu Chenggen Ph.D. (Chinese Academy of Medical Sciences and Peking Union Medical College) for providing standards of YZG-331 and M2.

Liu et al. | Stability and Metabolic Diversity of YZG-331

Frontiers in Pharmacology | www.frontiersin.org 13 August 2017 | Volume 8 | Article 527
1 and 3 in humans, monkeys, rats, and minipigs. Biochem. Pharmacol. 90, 159–165. doi: 10.1016/j.bcp.2014.04.019
Yan, Z., and Caldwell, G. W. (2001). Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 1, 403–425. doi: 10.2174/1568026013395001
Yao, D., Li, Z., Huo, C., Wang, Y., Wu, Y., Zhang, M., et al. (2016). Identification of in vitro and in vivo metabolites of alantolactone by UPLC-TOF-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 103, 250–260. doi: 10.1016/j.jchromb.2016.08.034
Yengi, L. G., Leung, L., and Kao, J. (2007). The evolving role of drug metabolism in drug discovery and development. Pharm. Res. 24, 842–858. doi: 10.1007/s11095-006-9217-9
Zhang, Y., Li, M., Kang, R. X., Shi, J. G., Liu, G. T., and Zhang, J. J. (2012). NHBA isolated from Gastrodia elata exerts sedative and hypnotic effects in sodium pentobarbital-treated mice. Pharmacol. Biochem. Behav. 102, 450–457. doi: 10.1016/j.pbb.2012.06.002
Zisapel, N. (2012). Drugs for insomnia. Expert Opin. Emerg. Drugs 17, 299–317. doi: 10.1517/147282214.2012.690735
Zisapel, N. (2015). Current Phase II investigational therapies for insomnia. Expert Opin. Investig. Drugs 24, 401–411. doi: 10.1517/13543784.2015.987340

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Liu, Yang, Sheng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.